May 4 - May 5, 2024

2nd Biennial Miami Precision Medicine 2024 Conference

The 2nd Biennial Miami Precision Medicine (MPM) 2024 conference will bring together diverse experts in the field to share their knowledge and approaches in moving the precision medicine field towards routine practice. Precision Oncology- treating the right patient with the right treatment at the right time- has made substantial progress in developing novel and effective treatments that target specific molecular alterations in an increasing number of cancer types. The course will examine the treatment landscape based on published and emerging data.

Enter your email

By submitting you agree to the Terms & Privacy Policy

Overview

The conference will also illustrate the role of Artificial Intelligence (AI) in identifying patterns and innovative strategies for specific cancers and individual patient populations. An interdisciplinary molecular tumor board case discussion will emphasize the role of germline and genomic alterations in selecting targeted treatments as well as present relevant precision medicine clinical trials. The success of next-generation precision oncology depends not onlyon the discovery of new actionable disease characteristics and the integration of multi-omic data, but also on the dissemination of clinical information amongst healthcare providers and the ability of patients to access novel targeted anticancer therapies not only locally, but globally.

Patients and advocacy groups will have an opportunity to “sit at the table” and share their insight, learn about promising clinical trials and partner with physicians to develop new strategies tailored to their specific needs. The conference’s goal is to promote and facilitate awareness, education and equity in precision medicine cancer care and ultimately to identify and overcome barriers to precision medicine.

TARGET AUDIENCE

The educational activity is intended for adult and pediatric medical hematologists and oncologists, surgical and radiation oncologists, gynecologic oncologists, pharmacists, primary care physicians, physician assistants, advanced registered nurse practitioners, nurses, research members, residents, fellows, patients and patient-advocacy groups as well as other allied health professionals.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

• Expedite adoption of germline and genomic testing in clinical practice

• Interpret next generation sequencing (NGS) results

• Interpret results of a liquid biopsy (ctDNA)

• Explain the role of multi-omics in precision oncology

• Describe common molecular alterations and the role of molecular

diagnostic tests in different cancer types

• Summarize role of biomarkers in selection of targeted therapies and immunotherapies in different cancer types

• Recognize the emerging role of Artificial Intelligence in precision medicine

• Summarize recent and emerging data from key studies in clinical and translational cancer research for the following areas:

• Hematological malignancies (MDS, AML and Follicular Lymphoma), pediatric cancers, neuro-oncology, breast cancer, genitourinary cancer, gastrointestinal cancer, sarcoma, neuroendocrine tumors, lung cancer, melanoma, gynecological malignancies.

Implement strategies designed to improve the quality of cancer care,address barriers to optimal care and enhance the patient experience

• Identify the role of lifestyle intervention in the precision medicine care model

• Identify the role of scientific advances in the field of cancer biology and tumor pathogenesis

• Develop collaborations that will lead to improved clinical trial portfolio and clinical trial participation

• Interact with patients and patient advocacy groups to promote access to molecularly-driven therapies and available clinical trials

• Facilitate patient-oncology experts’ interaction and understanding of survivorship challenges in the era of precision medicine

ACCREDITATION

The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 11.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE AND CONFLICT OF

INTEREST MITIGATION

All conflicts of interest of any individual(s) in a position to control the content of this CME activity will be identified and mitigated prior to this educational activity being provided. Disclosure about provider and faculty relationships, or the lack thereof, will be provided to learners.